Adenovirus vector-based vaccines for human immunodeficiency virus type 1.
暂无分享,去创建一个
[1] L. Weinberger,et al. Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques , 1999, The Journal of experimental medicine.
[2] M. Kaleko,et al. Circumvention of Immunity to the Adenovirus Major Coat Protein Hexon , 1998, Journal of Virology.
[3] B. Moss,et al. Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector Boosting , 2003, Journal of Virology.
[4] H. Whittle,et al. Prevalence of Neutralizing Antibodies to Adenoviral Serotypes 5 and 35 in the Adult Populations of The Gambia, South Africa, and the United States , 2004, Clinical Diagnostic Laboratory Immunology.
[5] James M. Wilson,et al. “Stealth” Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung , 2001, Journal of Virology.
[6] H. Ertl,et al. Induction of CD8+ T Cells to an HIV-1 Antigen through a Prime Boost Regimen with Heterologous E1-Deleted Adenoviral Vaccine Carriers 1 , 2003, The Journal of Immunology.
[7] L. Babiuk,et al. Replication-Defective Bovine Adenovirus Type 3 as an Expression Vector , 1999, Journal of Virology.
[8] James M. Wilson,et al. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. , 2002, Human gene therapy.
[9] J. Wilson,et al. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. , 1996, Human gene therapy.
[10] B. Berkhout,et al. Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5 , 2004, Journal of Virology.
[11] P. Quax,et al. Exploiting the Natural Diversity in Adenovirus Tropism for Therapy and Prevention of Disease , 2002, Journal of Virology.
[12] S. Kostense,et al. Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors , 2004, Journal of Virology.
[13] R. Crystal,et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. , 1997, Human gene therapy.
[14] Qiang Liu,et al. Molecular basis of the inflammatory response to adenovirus vectors , 2003, Gene Therapy.
[15] Z. Xiang,et al. Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene Product , 2002, Journal of Virology.
[16] Jon Cohen. AIDS Vaccine Trial Produces Disappointment and Confusion , 2003, Science.
[17] A. Simon,et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.
[18] L. Leinwand,et al. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes , 1996, Journal of virology.
[19] L. Eisenlohr,et al. The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. , 2002, Human gene therapy.
[20] D. Brough,et al. The Coxsackievirus-Adenovirus Receptor Protein Can Function as a Cellular Attachment Protein for Adenovirus Serotypes from Subgroups A, C, D, E, and F , 1998, Journal of Virology.
[21] R. K. Evans,et al. Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene , 2003, Journal of Virology.
[22] M. McElrath,et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. , 1997, The New England journal of medicine.
[23] E. Furth,et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[24] B. Berkhout,et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector , 2004, AIDS.
[25] J. Gall,et al. Circumventing the immune response to adenovirus-mediated gene therapy. , 1996, Gene therapy.
[26] S. Kostense,et al. Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1 , 2004, The Journal of Immunology.
[27] Z. Xiang,et al. A Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag 1 , 2003, The Journal of Immunology.
[28] R. M. Burnett,et al. Replication-Defective Vector Based on a Chimpanzee Adenovirus , 2001, Journal of Virology.
[29] R. DeMatteo,et al. Long-lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppression , 1997, Journal of virology.
[30] J. Shiver,et al. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. , 2004, Annual review of medicine.
[31] S. Kostense,et al. Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.
[32] J. Bergelson,et al. Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.
[33] R. Crystal,et al. Antivector and antitransgene host responses in gene therapy. , 2000, Current opinion in molecular therapeutics.
[34] Z. Xiang,et al. Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier , 2003, Journal of Virology.
[35] A. Gaggar,et al. CD46 is a cellular receptor for group B adenoviruses , 2003, Nature Medicine.
[36] P. Quax,et al. Improved Adenovirus Vectors for Infection of Cardiovascular Tissues , 2001, Journal of Virology.
[37] S. Santra,et al. Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 Vaccines , 2003, Journal of Virology.
[38] R. Gregory,et al. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway , 1997, Gene Therapy.
[39] U. Greber,et al. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake , 2002, The Journal of cell biology.
[40] G. Nabel,et al. Enhanced Mucosal Immunoglobulin A Response of Intranasal Adenoviral Vector Human Immunodeficiency Virus Vaccine and Localization in the Central Nervous System , 2003, Journal of Virology.
[41] B. Harvey,et al. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. , 1996, Human gene therapy.
[42] I. Kovesdi,et al. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. , 1999, Science.
[43] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[44] H. Ertl,et al. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. , 1994, Immunity.
[45] T. Toner,et al. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. , 2002, Human gene therapy.
[46] J. Mascola,et al. Heterologous Envelope Immunogens Contribute to AIDS Vaccine Protection in Rhesus Monkeys , 2004, Journal of Virology.
[47] H. Ertl,et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.
[48] R. Koup,et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates , 2003, Nature.
[49] A. Sanchez,et al. Development of a preventive vaccine for Ebola virus infection in primates , 2000, Nature.
[50] H. Ertl,et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. , 1996, Gene therapy.
[51] M. Magnusson,et al. The Maturation of Murine Dendritic Cells Induced by Human Adenovirus Is Mediated by the Fiber Knob Domain* , 2003, Journal of Biological Chemistry.
[52] S. Kostense,et al. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. , 2004, Vaccine.
[53] H. Ertl,et al. Cytotoxic T-Lymphocyte Target Proteins and Their Major Histocompatibility Complex Class I Restriction in Response to Adenovirus Vectors Delivered to Mouse Liver , 1998, Journal of Virology.
[54] J. Gall,et al. Construction and Characterization of Hexon-Chimeric Adenoviruses: Specification of Adenovirus Serotype , 1998, Journal of Virology.
[55] E. Nagy,et al. Construction and characterization of recombinant porcine adenovirus serotype 5 expressing the transmissible gastroenteritis virus spike gene. , 2001, The Journal of general virology.
[56] James G. Herndon,et al. Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine , 2001, Science.
[57] J. Mcghee,et al. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. , 1997, Journal of immunology.
[58] R. Steinman,et al. Recombinant adenovirus is an efficient and non‐perturbing genetic vector for human dendritic cells , 1999, European journal of immunology.
[59] T. Tursz,et al. Immune Response to Recombinant Adenovirus in Humans: Capsid Components from Viral Input Are Targets for Vector-Specific Cytotoxic T Lymphocytes , 2000, Journal of Virology.
[60] D. Ho,et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.
[61] C. Rooney,et al. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. , 1998, Human gene therapy.
[62] D. Montefiori,et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.
[63] R. DeMatteo,et al. Prolongation of adenoviral transgene expression in mouse liver by T lymphocyte subset depletion. , 1996, Gene therapy.
[64] L. Babiuk,et al. Porcine adenovirus-3 as a helper-dependent expression vector. , 1999, The Journal of general virology.
[65] D. Casimiro,et al. T-cell response to adenovirus hexon and DNA-binding protein in mice , 2004, Gene Therapy.
[66] A. Thomson,et al. Recombinant Adenovirus Induces Maturation of Dendritic Cells via an NF-κB-Dependent Pathway , 2000, Journal of Virology.
[67] R. Crystal,et al. Modification to the Capsid of the Adenovirus Vector That Enhances Dendritic Cell Infection and Transgene-Specific Cellular Immune Responses , 2004, Journal of Virology.
[68] M. Imperiale,et al. Biology of adenovirus and its use as a vector for gene therapy. , 2004, Human gene therapy.
[69] C. Wohlfart,et al. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms , 1988, Journal of virology.
[70] G. Nemerow,et al. Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment , 1993, Cell.
[71] M. Strauss,et al. Ovine Adenovirus Vectors Overcome Preexisting Humoral Immunity against Human Adenoviruses In Vivo , 1999, Journal of Virology.
[72] P. Boulanger,et al. Adenovirus Hexon Protein Is a Potent Adjuvant for Activation of a Cellular Immune Response , 2002, Journal of Virology.
[73] R. Hay,et al. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. , 1992, The Journal of general virology.
[74] J. Leiden,et al. Immune responses to transgene–encoded proteins limit the stability of gene expression after injection of replication–defective adenovirus vectors , 1996, Nature Medicine.
[75] Henryk Mach,et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.
[76] M. Schilham,et al. Extensive Cross-Reactivity of CD4+ Adenovirus-Specific T Cells: Implications for Immunotherapy and Gene Therapy , 2003, Journal of Virology.
[77] A. van der Eb,et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. , 1998, Human gene therapy.